Navigation Links
Warner Chilcott Reports the Death of Its Director James Andress
Date:3/14/2008

ST. DAVID'S, Bermuda, March 14 /PRNewswire-FirstCall/ -- It is with a profound sense of loss that Warner Chilcott Limited (Nasdaq: WCRX) reports today that Mr. James G. Andress, a director of the Company, died on Tuesday, March 11, 2008.

Roger Boissonneault, Chief Executive Officer, President and Director of Warner Chilcott Limited, issued the following statement:

"We report the loss of Jim Andress with great sadness. Jim was instrumental in the development of this Company. His thoughtful guidance and counsel will be sorely missed. Our deepest sympathies go out to Jim's family."

Mr. Andress was appointed to the Company's board of directors in August of 2006, and at the time of his passing he also served as the co-chairman of the audit committee of the board of directors. Mr. Andress was a former Chairman of the Pharmaceuticals Group, Beecham Group, plc, former Chairman, Healthcare Products and Services of SmithKline Beecham, plc and former President and Chief Operating Officer of Sterling Drug, Inc. From 1996 to 2000, Mr. Andress served as Chairman and Chief Executive Officer of Warner Chilcott PLC (acquired by the Company's predecessor in September 2000). Mr. Andress also served on the board of directors of Sepracor, Inc., XOMA Ltd. and Allstate Insurance Company.

About Warner Chilcott

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. We are a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of our products. WCRX-G

Read more on http://www.warnerchilcott.com.


'/>"/>
SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
2. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
5. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., , TSX VENTURE: HTL , TORONTO, Nov... (TSX-V: HTL), formerly Calotto Capital Inc., a le...uments for the stem cell research and fertility cl...cial results for the third quarter ended September...enue was $1.46 million compared with $1.43 million...
(Date:11/24/2009)..., , SAN DIEGO, Nov. 24, 2009 /PRNewsw...daq: ARNA ) announced today that the company is...nual Health Care Conference on December 1, 2009 at...at the New York Palace Hotel in New York City. Jac...cer, is scheduled to provide an overview of the co...
(Date:11/24/2009)...,, BOZEN,Italy,November24/PRNewswire/--Healt...njointventurewithagroupofselected,investors.Thisre...e,nameHealthRoboticsCanada,Inc.andwillmarket,insta...ncept,whichincludesthe,revolutionaryproductofferin...oboticsCanadaInc.willalsoprovideassistanceonan"asn...
(Date:11/24/2009)..., Chemical Abstracts Serv...on, reports that China,s patent office is now the ...cations in chemistry. China trailed Japan,s patent...ion (WIPO), and the United States Patent and Trade...ssed the USPTO in 2005, WIPO in 2006, and exceeded...
Breaking Biology Technology:Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3
... 12 Anthera Pharmaceuticals, Inc., a,privately he...mmatory drugs,announced today that it has complete...urrent Acute coronary events with Near-term Cardio...designed to examine the impact of,varespladib (A-0...of an Acute,Coronary Syndrome (ACS) event. , "...
... Pharmasset, Inc. (Nasdaq: VRUS ) announced toda...have agreed with the FDA on the final design for a... of hepatitis C (HCV), slated to initiate in the f...at R7128 is advancing into a large phase 2b trial,...ief Medical Officer. "R7128 is the most advanced n...
...nuary 12 , - Reflects Strong International Gr...ding IP Management Specialist and Legal Support Se...llectual property,( http://www.cpaglobal.com ) (IP...outsourced legal support services, has today marke...ew brand worldwide. , Founded in 1969 as a spe...
Other Biology Technology:Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 2Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 2Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 5CPA Global Marks 40th Anniversary With Launch of New Brand 2CPA Global Marks 40th Anniversary With Launch of New Brand 3
(Date:11/25/2009)...ital to your health as what you eat, found researc... Their experiments in mice revealed that the daily...verthe body,s metabolic clearinghouseis mostly con...dian clock as conventional wisdom had it. , "If...umber of genes completely independent of the circa...
(Date:11/24/2009)...es from collapsing have been true life-savers. But...ed -- once the arteries are strengthened, they bec... but to leave them in place. , Prof. Meital Zilb...dical Engineering has developed a new patent-pendi... needed, then dissolves. , "Our new composite fi...
(Date:11/24/2009)...debate. A high-profile study a few years ago sugge...on from trees and leaves, evidence for a very clos...ems. , But new research from the University of W...ae provide a much richer diet for fish and other a...week in the Proceedings of the National Academy o...
Breaking Biology News(10 mins):Feeding the clock 2Feeding the clock 3A coating for life 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 1Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 2Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 3Go to the doctor 3F Only if Im really sick 52314 1Go to the doctor 3F Only if Im really sick 52314 2Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 1Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 2Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 3
...INGTON, Va., June 10 Stanley, Inc. (NYSE:,SXE), a...ssional services,to the U.S. federal government, a...ve agreement to acquire Oberon Associates, Inc. (O...d information technology services,company. The pur...cash,subject to certain working capital and other ...
...Scientists at the Institute of Food Research have ...re vulnerable to the development of tumours. , W... Biotechnology and Biological Sciences Research Co...ntrol these changes and delay or reverse the onset...hat play a role in the very earliest stages of col...
...Monash University research into heavy metal contam... the Gippsland Lakes has revealed high mercury lev.... , Researchers from the School of Biological Sc...he dolphins were within a range considered to caus...er than mercury levels found in populations around...
Other Biology News:Stanley to Acquire Oberon Associates 2Stanley to Acquire Oberon Associates 3Stanley to Acquire Oberon Associates 4'Addicted' cells provide early cancer diagnosis 2Mercury contamination found in stranded Victorian dolphins 2
CD25 MicroBeads, non-human primate from Miltenyi Biotec
...tors are designed for enhanced translation of clon...s, e.g. rabbit reticulocyte lysate. The maps for p...a(+) with the following exceptions: pCITE-2b(+) is... and Xcm I sites. Subtract 7 bp from all sites bey...
Mouse Anti-Human Non-SMC condensin II complex, subunit D3 (NCAPD3) Monoclonal Antibody, Unconjugated from Lifespan Biosciences
Flp-In T-REx Core Kit from Invitrogen
Biology Products: